natgillin/translations-raw huggingface dataset:
First, dFdCDP inhibits ribonucleotide reductase, which is uniquely responsible for catalysing the reactions that produce deoxynucleoside triphosphates (dCTP) for DNA synthesis. 
Najprej dFdCDP zavira ribonukleotidno reduktazo, ki je katalizira samo reakcije, ki tvorijo dezoksinukleozidne trifosfate (dCTP) za sintezo DNK.
Skin rash- allergic skin rash, frequently itchy Hair loss 
Kožni izpuščaj - alergisjki kožni izpuščaj, pogosto srbeč Izguba las
In general, for severe (Grade 3 or 4) nonhaematological toxicity, except nausea/vomiting, therapy with gemcitabine should be withheld or decreased depending on the judgement of the treating physician. 
Na splošno bi moral lečeči zdravnik pri hudi (Stopnja 3 ali 4) nehematološki toksičnosti, razen pri navzei/bruhanju, glede na oceno, prekiniti ali znižati odmerek gemcitabina.
PHARMACEUTICAL FORM AND CONTENTS 1 vial, powder for solution for infusion 
FARMACEVTSKA OBLIKA IN VSEBINA 1 viala, prašek za raztopino za infundiranje
Tiredness, feeling faint, becoming easily breathless or if you look pale (since you might have less haemoglobin than normal which is very common). 
Utrujenost, občutek omedlevice, se hitro zadihate ali izgledate bledi (ker imate morda manj hemoglobina kot bi morali, kar je zelo pogosto).
• Anaemia 
• Anemija
OTHER SPECIAL WARNING(S), IF NECESSARY Do not refrigerate the reconstituted solution 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Rekonstituirane raztopine ne shranjujte v hladilniku.
Each vial contains 200 or 1000 mg of gemcitabine. 
Vsaka viala vsebuje 200 ali 1.000 mg gemcitabina.
The MAH agreed to delete the indication in superficial bladder cancer and the CHMP accordingly proposed the following revised wording: 
Imetnik dovoljenja za promet z zdravilom se je strinjal glede izbrisa indikacije površinskega raka sečnega mehurja, CHMP pa je skladno s tem predlagal spodnje popravljeno besedilo:
Gemcitabine plus Paclitaxel arm (N=262) Grade 3 Grade 4 Grade 3 Grade 4 
Veja z gemcitabinom in paklitakselom (N=262) 3. stopnja 4. stopnja 3. stopnja 4. stopnja
Prior chemotherapy should have included an anthracycline unless clinically contraindicated. 
Predhodna kemoterapija mora vključevati antracikline, razen če so klinično kontraindicirani.
Heart attack (myocardial infarction) Low blood pressure 
Redki neželeni učinki Srčni napad (miokardni infarkt) Nizek krvni tlak
Laboratory Anaemia Thrombocytopaenia Neutropaenia Non-laboratory Febrile neutropaenia Fatigue Diarrhoea Motor neuropathy Sensory neuropathy *Grade 4 neutropaenia lasting for more than 7 days occurred in 12.6% of patients in the combination arm and 5.0% of patients in the paclitaxel arm. 
Laboratorijski Anemija Trombocitopenija Nevtropenija Ne-laboratorijski Febrilna nevtropenija Utrujenost Diareja Motorična nevtropenija 2 (0,8) Senzorna nevtropenija *Nevtropenija 4. stopnje, ki je trajala več kot 7 dni, se je pojavila pri 12,6 % bolnikov v veji s kombinacijo in pri 5,0 % bolnikov v veji z paklitakselom.
The MAH provided an updated posology taking into account the CHMP comments. 
Imetnik dovoljenja za promet z zdravilom je predložil posodobljene podatke o odmerjanju, pri tem pa upošteval pripombe CHMP.
Periodically you will have samples of your blood taken to evaluate your kidney and liver function. 
Redno vam bodo jemali vzorce vaše krvi, da preverijo delovanje vaših ledvic in jeter.
Gemcitabine is not recommended for use in children under 18 years of age due to insufficient data on safety and efficacy. 
Zaradi pomanjkanja podatkov glede varnosti in učinkovitosti, uporabe gemcitabina pri otrocih mlajših od 18 let ne priporočamo.
The CHMP reviewed the MAH responses and agreed that as a single agent, gemcitabine has a specific role in patients with a borderline performance status and elderly patients and that gemcitabine is an option between other treatments, although no specific agent has been identified to be better than others. 
CHMP je pregledal odgovore imetnika dovoljenja za promet z zdravilom in se strinjal, da ima gemcitabin kot samostojno sredstvo posebno vlogo pri bolnikih z mejnim statusom učinkovitosti ter starostnih bolnikih, in da je gemcitabin eno od možnih zdravljenj, čeprav ni bilo točno določeno nobeno sredstvo, ki bi bilo boljše od drugih.
In addition, the use of gemcitabine for the treatment of recurrent ovarian cancer has been widely recognized and the MAH therefore believes that carboplatin plus gemcitabine represents a valuable option for treating patients with recurrent ovarian cancer. 
Poleg tega je uporaba gemcitabina za zdravljenje ponovljenega raka jajčnikov široko priznana, tako da imetnik dovoljenja za promet z zdravilom verjame, da kombinacija karboplatina in gemcitabina predstavlja dragoceno možnost zdravljenja bolnic s ponovljenim rakom jajčnikov.
Skin scaling, ulceration or blister formation Injection site reactions 
Luščenje kože, gnojenje ali tvorba mehurjev Reakcije na mestu injiciranja
Studies done subsequently have suggested that it is feasible to administer gemcitabine at lower doses with concurrent radiotherapy with predictable toxicity, such as a phase II study in non-small cell lung cancer, where thoracic radiation doses of 66 Gy were applied concomitantly with an administration with gemcitabine (600 mg/m2, four times) and cisplatin (80 mg/m2 twice) during 6 weeks. 
Študije, ki so jih opravili naknadno, kažejo, da je možno dati gemcitabin v nižjih odmerkih s sočasno radioterapijo s predvidljivo toksičnostjo, kot v študiji faze II pri bolnikih z nedrobnoceličnim karcinomom pljuč, ki so v 6 tednih prejemali odmerke obsevanja prsnega koša 66 Gy sočasno z dajanjem gemcitabina (600 mg/m površine telesa, štirikrat) in cisplatina (80 mg/m površine telesa, dvakrat).
The CHMP retained the conservative age of 18 and also noted that information regarding hepatic impairment was included and therefore requested the MAH to further discuss patients with renal or hepatic impairment and whether severe impairment had significant effect on gemcitabine pharmacokinetics. 
CHMP je obdržal konzervativno starost 18 let, poleg tega pa opazil, da so prisotne tudi informacije o okvarjenih jetrih, zaradi česar je od imetnika dovoljenja za promet z zdravilom zahteval nadaljnjo razpravo o bolnikih z okvaro jeter ali ledvic in odgovor na vprašanje, ali je imela huda okvara vpliv na farmakokinetiko gemcitabina.
Gemcitabine is rapidly metabolised by cytidine deaminase in the liver, kidney, blood and other tissues. 
Gemcitabin se hitro presnavlja s citidinsko aminazo v jetrih, ledvicah, krvi in drugih tkivih.
Grade 3 and 4 Adverse Events Paclitaxel versus gemcitabine plus paclitaxel Number (%) of Patients Paclitaxel arm (N=259) 
Neželeni učinki 3. in 4. stopnje Paklitaksel proti gemcitabinu s paklitakselom Število (%) bolnikov Veja s paklitakselom (N=259)
Finally, a number of additional minor comments, including comments to remaining sections of the SPC, were made by the CHMP and implemented directly in the SPC text. 
CHMP je na koncu imel še številne majhne pripombe, ki so vključevale pripombe na ostala poglavja povzetka glavnih značilnosti zdravila in ki jih je vnesel naravnost v besedilo povzetka glavnih značilnosti zdravila.
Triphasic plasma concentration versus time curve, mean half-life of terminal phase - 65 hours (range 33-84 hr). 
Na trofaznem grafu plazemskih koncentracij v odvisnosti od časa je povprečni končni razpolovni čas - 65 ur (razpon 33-84 ur).
Regarding ovarian cancer, the MAH proposed a wording for combination use in this indication, although activity is shown by gemcitabine as a single agent, and provided a clinical expert report and supplementary information to support the indication. 
Glede raka jajčnikov je imetnik dovoljenja za promet z zdravilom predlagal besedilo, ki pri tej indikaciji narekuje kombinacijsko uporabo gemcitabina, čeprav je ta učinkoval tudi kot samostojno sredstvo, in je v podporo indikaciji predložil poročilo kliničnih specialistov ter dodatne informacije.
Cisplatin is given at a recommended dose of 70 mg/m2 on Day 1 following gemcitabine or day 2 of each 28-day cycle. 
Cisplatin dajemo v priporočenem odmerku 70 mg/m površine telesa 1. dan po gemcitabinu ali 2. dan vsakega 28-dnevnega ciklusa.
Gemcitabine can suppress bone marrow function as manifested by leucopaenia, thrombocytopaenia and anaemia. 
Gemcitabin lahko zavre delovanje kostnega mozga, kar se izrazi kot levkopenija, trombocitopenija in anemija.
The other ingredients are mannitol (E421), sodium acetate, hydrochloric acid and sodium hydroxide. 
Pomožni snovi so manitol (E421), natrijev acetat, klorovodikova kislina in natrijev hidroksid.
Radiation injury has been reported on targeted tissues (e.g. oesophagitis, colitis, and pneumonitis) in association with both concurrent and non-concurrent use of gemcitabine. 
O obsevalnih poškodbah so poročali na ciljnih tkivih (npr. ezofagitis, kolitis in pnevmonitis) v povezavi s sočasno in ne-sočasno uporabo gemcitabina.
Overall, the MAH therefore considered gemcitabine plus paclitaxel combination chemotherapy to be an effective regimen in patients with metastatic breast cancer, with an expected and manageable toxicity and a favourable risk-benefit profile. 
Imetnik dovoljenja za promet z zdravilom je tako v splošnem menil, da je kombinacijska kemoterapija z gemcitabinom in paklitakselom učinkovita terapija za bolnike z metastatskim rakom dojk, ki ima pričakovano in obvladljivo toksičnost in ugoden profil tveganj in koristnih učinkov.
Dose-limiting adverse reactions are reductions in thrombocyte, leucocyte and granulocyte counts (see section 4.2). 
Neželeni učinki, zaradi katerih je treba odmerek omejiti, so znižanja koncentracij trombocitov, levkocitov in granulocitov (glejte poglavje 4.2).
Gemcitabine should be used with caution in patients with hepatic insufficiency or with impaired renal function as there is insufficient information from clinical studies to allow clear dose recommendation for this patient population (see section 4.2). 
Gemcitabin moramo uporabljati previdno pri bolnikih z jetrnim popuščanjem ali z okvarjenim delovanjem ledvic, ker je premalo podatkov iz kliničnih študij, ki bi omogočali jasna priporočila za odmerjanje pri teh skupinah bolnikov (glejte poglavje 4.2).
Instructions for reconstitution (and further dilution, if performed) The only approved diluent for reconstitution of gemcitabine sterile powder is sodium chloride 9 mg/ml (0.9%) solution for injection (without preservative). 
Navodila za rekonstitucijo (in nadaljnjo razredčitev, če je opravljena) Edini odobreni vehikel za rekonstitucijo sterilnega praška gemcitabina je natrijev klorid 9 mg/ml (0,9 %) raztopina za injiciranje (brez konzervansa).
Gemzar 1000 mg contains: 
Gemzar 1.000 mg vsebuje:
In a randomised phase III study, 356 patients with advanced epithelial ovarian carcinoma who had relapsed at least 6 months after completing platinum based therapy were randomised to therapy with gemcitabine and carboplatin (GCb), or carboplatin (Cb). 
Karcinom jajčnika V randomizirani študiji faze III s 365 bolniki z napredovalim epitelijskim karcinomom jajčnika, ki so imeli relaps najmanj 6 mesecev po zaključeni terapiji na osnovi platine, so bili randomizirani na terapijo z gemcitabinom in karboplatinom (GCb) ali karboplatinom (Cb).
Do not use after the expiry date (EXP) which is stated on the carton. 
Zdravila Gemzar ne smete uporabljati po datumu izteka roka uporabnosti (Uporabno do:), ki je naveden na škatli.
Bone-marrow suppression is usually mild to moderate and mostly affects the granulocyte count (see section 4.2) 
Zaviranje kostnega mozga je običajno blago do zmerno in prizadane zlasti koncentracijo granulocitov (glejte poglavje 4.2)
For Section 4.4, the MAH addressed impaired renal and hepatic function, paediatric recommendations and concomitant administration of gemcitabine and radiotherapy. 
Za poglavje 4.4 je imetnik dovoljenja za promet z zdravilom obravnaval okvaro jetrne in ledvične funkcije, priporočila za pediatrične bolnike in sočasno uporabo gemcitabina ter zdravljenja z obsevanjem.
• ovarian cancer, together with carboplatin. 
• rak jajčnika, skupaj s karboplatinom
Gemzar (gemcitabine) is a pyrimidine antagonist (an antimetabolite) that is metabolised intracellularly to active diphosphate and triphosphate nucleosides which inhibit DNA synthesis. 
Zdravilo Gemzar (gemcitabin) je antagonist pirimidina (antimetabolit), ki se metabolizira znotraj celic v aktivni difosfat in trifosfat nukleozid, ki zavirata sintezo DNK.
The MAH agreed that platinum-based combination therapies are the standard of care but defended the use of gemcitabine monotherapy in the treatment of elderly patients and patients with a Performance Status of 2, as these groups are at higher risk for chemotherapy-related morbidities or in cases where platinum-based combinations cannot be tolerated. 
Imetnik dovoljenja za promet z zdravilom se je strinjal, da so kombinacijske terapije na osnovi platine standardna nega, vendar je zagovarjal uporabo monoterapije z gemcitabinom pri zdravljenju starostnih bolnikov in bolnikov s statusom učinkovitosti 2, ker sta ti skupini bolj izpostavljeni tveganju s kemoterapijo povezane obolevnosti, ali v primerih, ko bolniki kombinacij na osnovi platine ne morejo prenašati.
Adult respiratory distress syndrome (see section 4.4) 
Sindrom dihalne stiske pri odraslem (glejte poglavje 4.4)
The total volume after reconstitution is 5.26 ml (200 mg vial) or 26.3 ml (1000 mg vial) respectively. 
Celotni volumen po rekonstituciji je 5,26 ml (200 mg viala) ali 26,3 ml (1.000 mg viala).
The CHMP reviewed the information regarding the use of Gemcitabine in ovarian cancer and was of the opinion that the combination gemcitabine/carboplatin is an option in second line therapy in patients with sensitive platinum disease and an alternative in patients with previous paclitaxel/carboplatin toxicity (Therefore the CHMP retained the indication in ovarian cancer in the harmonised SPC, with the wording: 
CHMP je pregledal informacije o uporabi gemcitabina pri raku jajčnikov in je bil mnenja, da je kombinacija gemcitabina/karboplatina možnost za zdravljenje druge izbire pri bolnicah, katerih bolezen je občutljiva na platino, in alternativa za bolnice, ki so predhodno pokazale toksične reakcije na paklitaksel/karboplatin (zaradi tega je CHMP v usklajenem povzetku glavnih značilnosti zdravila obdržal indikacijo za raka jajčnikov, izraženo z besedilom:
Renal clearance was 2 to 7 l/hr/m2. 
Ledvični očistek je bil 2 do 7 l/h/m površine telesa.
Renal failure may not be reversible with discontinuation of therapy and dialysis may be required. 
Ob prekinitvi zdravljenja ledvično popuščanje morda ne bo povratno in bo bolnik potreboval dializo.
Before the first infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function. 
Pred prvo infuzijo vam bodo vzeli vzorce vaše krvi, da preverijo, če imate ustrezno delovanje ledvic.
Cellular metabolism and mechanism of action: Gemcitabine (dFdC), which is a pyrimidine antimetabolite, is metabolised intracellularly by nucleoside kinase to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. 
Celična presnova in mehanizem delovanja: Gemcitabin (dFdC), ki je pirimidinski antipresnovek, znotrajcelično presnavlja nukleozidna kinaza do aktivnih difosfatnih (dFdCDP)- in trifosfatnih (dFdCTP) nukleozidov.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 200 mg gemcitabine 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 200 mg gemcitabina
No specific studies were performed in severely renally or hepatically impaired patients but based on published literature, the MAH considered that there was no indication that these patients differ significantly from the mild to moderate renally impaired group, in terms of Cmax or clearance. 
Pri bolnikih s hudo okvaro ledvic ali jeter ni bilo izvedenih nobenih študij, temveč se je imetnik dovoljenja zanašal na izdano literaturo in menil, da ni indikacij o znatnih razlikah med temi bolniki in bolniki z blago do zmerno okvaro ledvic, kar se tiče izčistka Cmax.
After gemcitabine is incorporated into DNA, one additional nucleotide is added to the growing DNA strands. 
Ko se gemcitabin vgradi v DNK, se DNK vijačnici, ki se tvori doda en nukleotid.
A randomised phase III study of 405 patients with advanced or metastatic urothelial transitional cell carcinoma showed no difference between the two treatment arms, gemcitabine/cisplatin versus methotrexate/vinblastine/adriamycin/cisplatin (MVAC), in terms of median survival (12.8 and 14.8 months respectively, p=0.547), time to disease progression (7.4 and 7.6 months respectively, p=0.842) and response rate (49.4% and 45.7% respectively, p=0.512). 
Randomizirana študija faze III s 405 bolniki z napredovalim ali metastatskim urotelijskim karcinomom tranzicijskih celic ni pokazala nobene razlike med dvema vejama zdravljenja, gemcitabin/cisplatin proti metotreksat/vinblastin/adriamicin/cisplatin (MVAC) glede povprečnega preživetja (12,8 in oziroma 14,8 mesecev, p=0,547), časa do napredovanja bolezni (7,4 in oziroma 7,6 mesecev, p=0,842) ter stopnje odziva (49,4 % in 45,7 %, p=0,512).
Anaphylactic reaction (severe hypersensitivity/ allergic reaction) Sloughing of skin and severe skin blistering 
Zvišano število krvnih ploščic Anafilaktična reakcija (preobčutljivost/alergijska reakcija) Krastava koža in hudo mehurjenje kože
In summary the MAH has deleted the indication for intravesical use and for 5-FUrefractory pancreatic cancer while the indication in ovarian cancer has been justified. 
Imetnik dovoljenja za promet z zdravilom je torej zbrisal indikacijo za intravezikalno uporabo in za 5-FU neodzivne bolnike z rakom trebušne slinavke, medtem ko je indikacijo za raka jajčnikov uspešno zagovarjal.
Administration of gemcitabine in patients with concurrent liver metastases or a pre-existing medical history of hepatitis, alcoholism or liver cirrhosis may lead to exacerbation of the underlying hepatic insufficiency. 
Dajanje gemcitabina bolnikom s sočasnimi jetrnimi zasevki ali hepatitisom, alkoholizmom ali jetrno cirozo v anamnezi lahko vodi v poslabšanje osnovnega popuščanja delovanja jeter.
• Mild proteinuria 
• Blaga proteinurija
• Allergic skin rash frequently associated with pruritus 
• Alergijski kožni izpuščaj, pogosto s srbenjem
Intracellular concentrations increase in proportion to gemcitabine doses of 35-350 mg/ m2/30-minutes, which give steady state concentrations of 0.4-5 µg/ml. 
Znotrajcelične koncentracije naraščajo skladno z odmerki gemcitabina 35 do 350 mg/m2 površine telesa/30-minut, kar daje koncentracije v stanju dinamičnega ravnovesja 0,4-5 µg/ml.
Frequency grouping 
Skupina pogostnosti
Radiation toxicity- scarring of the air sacs of the lung associated with radiation therapy Ischaemic colitis (inflammation of the lining of the large bowel, caused by reduced blood supply) Heart failure 
Radiacijska toksičnost - brazgotinjenje pljučnih mešičkov pljuč v povezavi z radiacijsko terapijo Ishemični kolitis (vnetje sluznice debelega črevesa, ki jo povzroči zmanjšan pritok krvi) Srčno popuščanje
Arrythmias, predominantly supraventricular in nature Heart failure 
Aritmije, zlasti supraventrikularne Srčno popuščanje
The MAH focused the discussion on the pivotal randomized Phase 3 Study JHQJ, and the main supportive single-arm Phase 2 Study JHRW. 
Imetnik dovoljenja za promet z zdravilom je razpravo osredotočil na osrednjo radomizirano študijo 3. faze JHQJ in glavno podporno študijo 2. faze JHRW z enim krakom.
The optimum regimen for safe administration of gemcitabine with therapeutic doses of radiation has not yet been determined in all tumour types. 
Za vse vrste tumorjev še niso določili optimalnega režima za varno dajanje gemcitabina s terapevtskimi odmerki obsevanja.
Important information about some of the ingredients of Gemzar Gemzar contains 3.5 mg (< 1 mmol) of sodium in each 200 mg vial and 17.5 mg (< 1 mmol) sodium in each 1000 mg vial. 
Pomembne informacije o nekaterih sestavinah zdravila Gemzar Zdravilo Gemzar vsebuje 3,5 mg (< 1 mmol) natrija v vsaki 200 mg viali ter 17,5 mg (< 1 mmol) natrija v vsaki 1.000 mg viali.
When prepared as directed, chemical and physical in-use stability of reconstituted solutions of gemcitabine were demonstrated for 24 hours at 30°C. 
Če je pripravljeno v skladu z navodili, so dokazali kemijsko in fizikalno stabilnost med uporabo rekonstituirane raztopine gemcitabina za 24 ur pri 30 °C.
In fertility studies gemcitabine caused hypospermatogenesis in male mice (see section 5.3). 
V študijah plodnosti je gemcitabin povzročil hipospermatogenezo pri samcih miši (glejte poglavje 5.3).
After 377 deaths, the overall survival was 18.6 months versus 15.8 months (log rank p=0.0489, HR 0.82) in patients treated with gemcitabine/paclitaxel compared to patients treated with paclitaxel and the overall response rate was 41.4% and 26.2% respectively (p= 0.0002). 
Po 377 smrtih je bilo pri bolnikih, zdravljenih z gemcitabin/paklitaksel v primerjavi z bolniki, zdravljenimi s paklitakselom celotno preživetje 18,6 mesecev proti 15,8 mesecev (logaritemska stopnja p=0,0489, HR 0,82,) ter celotna stopnja odziva 41,4 % in oziroma 26,2 % (p=0,0002).
Each vial contains 200 or 1000 mg of gemcitabine (as gemcitabine hydrochloride). 
Vsaka viala vsebuje 200 ali 1.000 mg gemcitabina (v obliki gemcitabinijevega klorida).
Therefore, men being treated with gemcitabine are advised not to father a child during and up to 6 months after treatment and to seek further advice regarding cryoconservation of sperm prior to treatment because of the possibility of infertility due to therapy with gemcitabine. 
Zato je moškim, zdravljenim z gemcitabinom, potrebno svetovati naj ne spočenjajo otroka med in do 6 mesecev po zdravljenju ter naj poiščejo nadaljnji nasvet glede kriokonzervacije semena pred zdravljenjem, zaradi možne neplodnosti zaradi zdravljenja z gemcitabinom.
Plasma concentrations of the parent compound following a dose of 1,000 mg/m2/30-minutes are greater than 5 µg/ml for approximately 30-minutes after the end of the infusion, and greater than 0.4 µg/ml for an additional hour. 
Plazemska koncentracija izhodiščne snovi po odmerku 1.000 mg/m površine telesa/30 min je večja kot 5 µg/ml za približno 30 minut po zaključku infuzije in večja kot 0,4 µg/ml še eno uro.
The resulting solution is clear and ranges in colour from colourless to light straw-coloured. 
Rekonstituirana raztopina je bistra, barve v razponu od brezbarvne do rahlo slamnato-obarvane raztopina.
Treatment will start on day 1 of the next cycle once the absolute granulocyte count reaches at least 1,500 (x106/l) and the platelet count reaches 100,000 (x106/l). 
Zdravljenje se bo začelo na 1. dan naslednjega ciklusa ko bo absolutna koncentracija granulocitov dosegla vsaj 1.500 (x10
For Section 4.2, the MAH proposed a harmonised wording, addressing in particular the sections about dosage adjustment, about impaired renal function and on precautions in administration. 
Imetnik dovoljenja za promet z zdravilom je predlagal uskladitev besedila v poglavju 4.2, še posebej v podpoglavjih o prilagajanju odmerka, o poslabšanem delovanju ledvic in o varnostnih ukrepih pri dajanju zdravila.
Gemzar may make you feel sleepy, particularly if you have consumed any alcohol. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Gemzar vam lahko povzroči občutek zaspanosti, zlasti če ste zaužili kaj alkohola.
• Dyspnoea -usually mild and passes rapidly without treatment 
• Dispneja - zlasti blaga in mine hitro brez zdravljenja
Serious liver damage, including liver failure 
Resna poškodba jeter, vključno s jetrno popuščanje Kap
• Thrombocytopaenia 
• Trombocitopenija
Clinical findings consistent with the haemolytic uraemic syndrome (HUS) were rarely reported in patients receiving gemcitabine (see section 4.8). 
Pri bolnikih, ki so prejemali gemcitabin so redko poročali o kliničnih ugotovitvah, skladnih s hemolitičnim uremičnim sindromom (HUS) (glejte poglavje 4.8).